Skip to main content
    V

    Veracyte Inc (VCYT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $24.01
    -0.32 (-1.32%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Veracyte Inc (VCYT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Veracyte (VCYT) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Veracyte reported EPS of $0.38, above the $0.29 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    -0.63%
    Streak
    10 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.41
    Range$0.30 - $0.53
    14 analysts
    Revenue Consensus
    $154.39M
    Range$145.33M - $168.00M
    14 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.33
    Range$0.29 - $0.41
    9 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.44-24.9%
    60d ago$0.44-24.9%
    30d ago$0.45-25.3%
    7d ago$0.44-24.6%
    Current$0.33
    Revenue Consensus
    $148.48M
    Range$144.57M - $154.90M
    8 analysts

    Next Report

    VCYT has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 22.6% below the $0.53 reported for the quarter ended Dec 31, 2025.

    VCYT Earnings Call

    The latest VCYT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, VCYT beat 27, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $151.75M, up 15.1% from $131.87M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.38$0.29N/A+31.03%Beat-25.5%110 up, 1 downNov 4, 2026$151.75M
    Jun 30, 2026$0.37$0.29N/A+27.59%Beat-15.9%116 up, 2 downJul 30, 2026$150.32M
    Mar 31, 2026$0.52$0.33$0.23 - $0.37+57.58%Beat+67.7%117 up, 3 downMay 5, 2026$139.07M
    Dec 31, 2025$0.53$0.39$0.37 - $0.46+35.90%Beat+47.2%105 up, 0 downFeb 25, 2026$140.64M
    Sep 30, 2025$0.51$0.32$0.30 - $0.35+59.38%Beat+54.5%110 up, 0 downNov 4, 2025$131.87M
    Jun 30, 2025$0.44$0.30$0.25 - $0.34+46.67%Beat+46.7%83 up, 3 downAug 6, 2025$130.16M
    Mar 31, 2025$0.31$0.20$0.15 - $0.25+55.00%Beat+675.0%110 up, 2 downMay 7, 2025$114.47M
    Dec 31, 2024$0.36$0.26$0.12 - $0.30+40.02%BeatN/A107 up, 1 downFeb 24, 2025$118.63M
    Sep 30, 2024$0.33$0.17N/A+94.12%BeatN/A72 up, 0 downNov 6, 2024$115.86M
    Jun 30, 2024$0.30-$0.01-$0.06 - $0.06N/AN/AN/A81 up, 0 downAug 6, 2024$114.43M
    Mar 31, 2024$0.04-$0.10N/A+140.00%BeatN/A61 up, 0 downMay 7, 2024$96.84M
    Dec 31, 2023-$0.39-$0.09-$0.14 - -$0.06-333.33%MissN/A62 up, 0 downFeb 22, 2024$98.20M
    Sep 30, 2023-$0.41-$0.13-$0.17 - -$0.12-215.38%MissN/A80 up, 0 downNov 7, 2023$90.11M
    Jun 30, 2023-$0.12-$0.14-$0.17 - -$0.12+14.29%BeatN/A80 up, 0 downAug 8, 2023$90.32M
    Mar 31, 2023-$0.11-$0.11-$0.17 - -$0.050.00%In lineN/A81 up, 1 downMay 4, 2023$82.42M
    Dec 31, 2022-$0.05-$0.15-$0.20 - -$0.11+66.67%BeatN/A71 up, 0 downFeb 22, 2023$80.30M
    Sep 30, 2022-$0.12-$0.23-$0.29 - -$0.19+47.83%BeatN/A70 up, 1 downNov 2, 2022$75.59M
    Jun 30, 2022-$0.13-$0.22-$0.27 - -$0.17+40.91%BeatN/A70 up, 0 downAug 2, 2022$72.86M
    Mar 31, 2022-$0.20-$0.23-$0.29 - -$0.19+13.04%BeatN/A90 up, 0 downMay 3, 2022$67.78M
    Dec 31, 2021-$0.15-$0.16-$0.22 - -$0.06+6.25%BeatN/A9N/AFeb 28, 2022$67.34M
    Sep 30, 2021-$0.20-$0.14-$0.22 - -$0.08-42.86%MissN/A8N/ANov 9, 2021$60.37M
    Jun 30, 2021-$0.13-$0.25-$0.30 - -$0.21+48.00%BeatN/A10N/AJul 29, 2021$55.10M
    Mar 31, 2021-$0.66-$0.12-$0.17 - -$0.05-450.00%MissN/A8N/AMay 10, 2021$36.70M
    Dec 31, 2020-$0.14-$0.10-$0.18 - -$0.06-40.00%MissN/A8N/AFeb 17, 2021$34.54M
    Sep 30, 2020-$0.08-$0.19-$0.25 - -$0.17+57.89%BeatN/A6N/ANov 2, 2020$31.12M
    Jun 30, 2020-$0.22-$0.27-$0.34 - -$0.13+18.52%BeatN/A5N/AJul 30, 2020$20.70M
    Mar 31, 2020-$0.24-$0.20-$0.27 - -$0.15-20.00%MissN/A6N/AMay 6, 2020$31.12M
    Dec 31, 2019-$0.15-$0.07-$0.09 - -$0.06-114.29%MissN/A6N/AFeb 25, 2020$29.73M
    Sep 30, 2019-$0.02-$0.07-$0.12 - -$0.04+71.43%BeatN/A6N/AOct 22, 2019$30.97M
    Jun 30, 2019-$0.05-$0.09-$0.14 - -$0.07+44.44%BeatN/A5N/AJul 30, 2019$30.14M
    Mar 31, 2019-$0.05-$0.07-$0.18 - -$0.02+28.57%BeatN/A4N/AApr 30, 2019$29.53M
    Dec 31, 2018-$0.08-$0.15-$0.19 - -$0.10+46.67%BeatN/A4N/AFeb 25, 2019$25.75M
    Sep 30, 2018-$0.12-$0.21N/A+42.86%BeatN/A4N/AOct 29, 2018$23.47M
    Jun 30, 2018-$0.18-$0.26-$0.30 - -$0.23+30.77%BeatN/A5N/AJul 23, 2018$22.75M
    Mar 31, 2018-$0.27-$0.25-$0.27 - -$0.22-8.00%MissN/A5N/AMay 1, 2018$20.04M
    Dec 31, 2017-$0.24-$0.20-$0.24 - -$0.18-20.00%MissN/A5N/AFeb 27, 2018$19.60M
    Sep 30, 2017-$0.21-$0.21-$0.32 - -$0.190.00%In lineN/A6N/ANov 6, 2017$17.52M
    Jun 30, 2017-$0.22-$0.25-$0.27 - -$0.22+12.00%BeatN/A4N/AJul 31, 2017$18.41M
    Mar 31, 2017-$0.24-$0.23N/A-4.35%MissN/AN/AN/AMay 3, 2017$16.43M
    Dec 31, 2016-$0.14-$0.26N/A+46.15%BeatN/AN/AN/AMar 1, 2017$18.26M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.79, up 73.8% from the year before. It was -$1.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.79+73.8%
    Dec 31, 2024$1.03N/A
    Dec 31, 2023-$1.03N/A
    Dec 31, 2022-$0.50N/A
    Dec 31, 2021-$1.14N/A
    Dec 31, 2020-$0.68N/A
    Dec 31, 2019-$0.27N/A
    Dec 31, 2018-$0.65N/A
    Dec 31, 2017-$0.91N/A
    Dec 31, 2016-$1.10N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,800 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,82014
    2026Q2Jun 30, 20268,17414
    2026Q1Mar 31, 20265,74810
    2025Q4Dec 31, 20259,36516
    2025Q3Sep 30, 20257,15814
    2025Q2Jun 30, 20258,91515
    2025Q1Mar 31, 202510,15513
    2024Q4Dec 31, 20248,93714

    2026Q3 Earnings Call

    Opening remarks

    Kelly Gura Director of Investor Relations Good afternoon, everyone, and thank you for joining us today to review Veracyte's third quarter 2026 financial results. Joining me on the call are Marc A. Stapley, our Chief Executive Officer, and Rebecca Chambers, our Chief Financial Officer. Dr. John Leite, our Chief Commercial Officer, will also be available for Q&A. Earlier this afternoon, we issued a press release detailing our third quarter financial results, and we posted an accompanying presentation in the Investors section of our website. Before we begin, I would like to remind you that statements we make during this call include forward-looking statements, as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance that they will prove to be correct. The company undertakes no obligation to update any forward-looking statements, except as required by law. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with the Securities and Exchange Commission, including the most recent Forms 10-Q and 10-K. In addition, this call will include certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP financial measures are included in today's earnings release, accessible from the Investors section of Veracyte's website. I will now turn the call over to Marc A. Stapley, Veracyte's CEO.

    Marc A. Stapley CEO Thank you, Kelly, and thank you all for joining us today. Third quarter revenue increased 15% year over year to $152 million, and we delivered another quarter of strong profitability and cash generation. Afirma exceeded expectations, while Decipher prostate volume was lower than we expected. Today, we will share our observations regarding these trends, the steps we are taking to support future growth, and why we remain confident in the long-term opportunity for all of our tests. First, I would like to highlight some of the exciting momentum we are seeing across our portfolio. We have made good progress advancing our breast and bladder strategies over the last few months, with the launches of Prosigna LDT for breast cancer and TruMRD for muscle-invasive bladder cancer, or MIBC. In September, we strengthened our urology portfolio through the acquisition of Convergent Genomics, adding a technology platform that complements our tissue- and blood-based capabilities across the bladder cancer continuum. We also advanced our market access strategies in breast, prostate, and bladder cancer, helping preserve and expand access to our valuable tests for Medicare-eligible patients. Now I will walk through our performance across each of our growth drivers. Starting with Decipher Prostate, we delivered nearly 30,000 tests in the third quarter, representing 12% year-over-year growth, with volume approximately 1,000 tests lower than we expected.

    Frequently Asked Questions About VCYT

    When is Veracyte's next earnings date?

    Veracyte's next earnings report is expected for Feb 22, 2027.

    Did VCYT beat earnings estimates last quarter?

    Yes. Veracyte reported EPS of $0.38 for the quarter ended Sep 30, 2026, above the $0.29 estimate, a 31.03% surprise.

    What EPS do analysts expect from VCYT next quarter?

    The consensus EPS estimate for Veracyte for the quarter ending Dec 31, 2026 is $0.41 from 14 analysts, with estimates from $0.30 to $0.53.

    How often does VCYT beat earnings estimates?

    Veracyte beat the EPS estimate in each of the last 9 quarters, with an average surprise of +49.70%.